We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+15.94%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$732M
AUM Growth
-$316M
Cap. Flow
-$376M
Cap. Flow %
-51.38%
Top 10 Hldgs %
46.9%
Holding
119
New
21
Increased
21
Reduced
25
Closed
28

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$26M
2
INSM icon
Insmed
INSM
+$25.6M
3
TRVI icon
Trevi Therapeutics
TRVI
+$7.99M
4
ELVN icon
Enliven Therapeutics
ELVN
+$7.57M
5
VTYX
Ventyx Biosciences
VTYX
+$7.33M

Top Sells

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$17.5M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$16.8M
3
MRUS
Merus
MRUS
+$11.8M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$8.19M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$7.44M

Sector Composition

Rank Sector Weight
1 Healthcare 87.76%
2 Financials 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
26
Spyre Therapeutics
SYRE
$8.45B
$9.08M 1.24%
606,678
+125,000
+26% +$1.85M
ELVN icon
27
Enliven Therapeutics
ELVN
$3.69B
$8.02M 1.1%
+400,000
New +$7.57M
PRQR icon
28
ProQR Therapeutics
PRQR
$248M
$7.14M 0.98%
3,499,512
+215,000
+7% +$350K
AKBA icon
29
Akebia Therapeutics
AKBA
$343M
$7.1M 0.97%
1,950,000
+450,000
+30% +$1.24M
INZY
30
DELISTED
Inozyme Pharma
INZY
$7M 0.96%
1,749,359
-2,118,351
-55% -$5.25M
AUTL
31
Autolus Therapeutics
AUTL
$373M
$6.94M 0.95%
3,045,000
– –
ORKA
32
Oruka Therapeutics
ORKA
$5.53B
$6.76M 0.92%
603,479
+58,117
+11% +$606K
EXEL icon
33
CALL
Exelixis
EXEL
$14B
$6.61M 0.9%
150,000
+15,000
+11% +$600K
BBIO icon
34
BridgeBio Pharma
BBIO
$15.8B
$6.48M 0.88%
150,000
-150,000
-50% -$5.46M
VRDN icon
35
Viridian Therapeutics
VRDN
$2.05B
$5.45M 0.74%
390,000
– –
AXSM icon
36
Axsome Therapeutics
AXSM
$11.4B
$5.22M 0.71%
50,000
-50,000
-50% -$5.29M
ERAS icon
37
Erasca
ERAS
$6.53B
$5.19M 0.71%
4,085,787
+744,268
+22% +$996K
NAMS icon
38
NewAmsterdam Pharma
NAMS
$3.47B
$4.98M 0.68%
275,000
-50,000
-15% -$912K
CBIO
39
Crescent Biopharma
CBIO
$537M
$4.52M 0.62%
+280,031
New +$5.92M
ROIV icon
40
Roivant Sciences
ROIV
$24.5B
$4.51M 0.62%
400,000
+250,000
+167% +$2.71M
CRNX icon
41
Crinetics Pharmaceuticals
CRNX
$8.88B
$4.38M 0.6%
152,252
– –
PCVX icon
42
Vaxcyte
PCVX
$8.01B
$4.06M 0.56%
125,000
+100,000
+400% +$3.28M
PCSC
43
Perceptive Capital Solutions
PCSC
$123M
$3.71M 0.51%
350,000
– –
MRUS
44
DELISTED
Merus
MRUS
$3.68M 0.5%
70,000
-251,962
-78% -$11.8M
CATX icon
45
Perspective Therapeutics
CATX
$333M
$3.61M 0.49%
1,050,000
-1,174,196
-53% -$3.1M
AVTX icon
46
Avalo Therapeutics
AVTX
$957M
$3.03M 0.41%
607,872
-49,282
-7% -$230K
OACCU
47
Oaktree Acquisition Corp III Life Sciences Unit
OACCU
$2.65M 0.36%
250,000
– –
JAZZ icon
48
Jazz Pharmaceuticals
JAZZ
$15.3B
$2.65M 0.36%
+25,000
New +$2.72M
MNPR icon
49
Monopar Therapeutics
MNPR
$709M
$2.42M 0.33%
67,500
+5,500
+9% +$200K
RAPP
50
Rapport Therapeutics
RAPP
$1.92B
$2.27M 0.31%
+199,643
New +$2.12M
1
2
3 4 5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q2 2025 Portfolio in Review

As of Q2 2025, Affinity Asset Advisors held 119 positions worth $732M, down 30% from $1.05B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Affinity Asset Advisors withdrew a net $376M in Q2 2025, closing 28 positions and reducing 25 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $16.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 55% a quarter earlier, followed by Financials.

Against the trend, Affinity Asset Advisors opened a new position in Blueprint Medicines worth $32M.

  • Affinity Asset Advisors's largest Q2 2025 buy was Blueprint Medicines: 250,000 shares worth $32M.
  • Affinity Asset Advisors added most to Insmed in Q2 2025, an estimated $25.6M increase.
  • Affinity Asset Advisors's biggest Q2 2025 reduction was Apogee Therapeutics, cutting an estimated $17.5M.
  • Affinity Asset Advisors fully exited State Street SPDR S&P 500 ETF Trust in Q2 2025, selling an estimated $16.8M.
  • Affinity Asset Advisors's ten largest holdings make up 47% of its $732M portfolio in Q2 2025.
  • Affinity Asset Advisors opened 21 new positions and closed 28 in Q2 2025.
  • Affinity Asset Advisors's portfolio value fell 30% quarter-over-quarter to $732M.

Based on Affinity Asset Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.